{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-069810","form_type":"8-K","ticker":"RNAZ","cik":"0001829635","company_name":"Transcode Therapeutics, Inc.","filed_at":"2026-06-03T12:08:44+00:00","discovered_at":"2026-06-03T12:10:00.307573+00:00","generated_at":"2026-06-03T12:10:11.277547+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"TransCode Phase 1a TTX-MC138 trial meets safety endpoint; 64% stable disease at 6 months","bullets":["16 patients received 86 doses; median treatment 11.3 weeks (range 4-52.4 weeks).","No dose-limiting toxicities; recommended Phase 2a dose set at 4.8 mg/kg.","9 of 14 evaluable patients (64%) achieved stable disease lasting ≥6 months.","Three patients remain on study (at 21, 16, and 14 cycles); one thyroid cancer patient had dramatic thyroglobulin drop.","Phase 2a trial initiated in ctDNA-positive colorectal cancer after curative-intent therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-069810","json":"https://secwatch.observer/filing/0001104659-26-069810.json","markdown":"https://secwatch.observer/filing/0001104659-26-069810.md","text":"https://secwatch.observer/filing/0001104659-26-069810.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829635/000110465926069810/0001104659-26-069810-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829635/000110465926069810/tm2616719d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T12:10:11.277547+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}